stretch core outlook
beyond improv upgrad buy
organ growth steadi cyno headwind dissip
upgrad buy neutral rais po
believ steadier foot organ growth upsid due
tuck-in boost breast health strength molecular diagnost mdx
biz fda warn letter annual cynosur cyno headwind like
bottom sale less controversi may allow
stock rerat investor focu organ growth view
amid concern recess see defens choic growth
valu rotat volatil inflect market overal revenu recur
think share provid predict less risk recess scenario
expect sustain optim capital-expenditure among hospit benefit base
bofaml hospit capital-expenditure survey conduct facil
intern would see smaller impact peer macro risk intensifi
much smaller intern busi exposur
grow portfolio women product
lead manufactur medic devic primarili focus improv
women health market share us mammographi market
also expand offer breast health suit liquid-bas
cytolog market cervic cancer screen domin us ct/ng std
test market gain signific share hpv grow test menu
women health well virolog assay drive signific upsid annuiti
rais estim po
rais organ growth estim beyond revenue
also rais ep
street introduc rais po base
ep believ deserv trade closer peer
given on-going organ growth improv ep growth potenti
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
core mammographi diagnost
busi deliv solid perform
believ steadier
foot organ growth upsid due
expand offer breast health strength
molecular diagnost mdx busi
believ cynosur cyno headwind less
controversi stock may allow
stock rerat investor focu
leader women health
breast health diagnost account sale
expand breast health busi
expand across breast health suit acquisit
regulatori polici tailwind may boost upgrad
blood screen divest servic tailwind continu
surgic biz tale two citi
myosur growth engin new product drive volum
novasur declin lessen multi-year process
cynosur bet pay
meaning turnaround expect near-term
skelet health oldest smallest
organ revenu growth upsid potenti
margin profil see improv
capit deploy plan tuck-in buyback
lead manufactur medic devic diagnost product
primarili focus improv women health largest market share
us mammographi market liquid-bas cytolog market
cervic cancer screen ct/ng chlamydia trachomatis/neisseria
gonorrhoea std sexual transmit diseas test market
gynecolog surgeri equip market compani also expand share
molecular diagnost market recov impact hasti medic
aesthet move via acquisit cynosur
four main tenet buy thesi first cynosur longer consid
controversi neg impact fda warn letter annual
come quarter allow investor focu organ growth second tuck-in
deal breast health vendor digit mammographi share
us fast grow molecular diagnost busi expand menu reviv
top-lin growth creat opportun intern expans potenti us
current sale third expect sustain optim overal capital-expenditure
well target spend diagnost imag among hospit benefit base
bofaml hospit capital-expenditure survey conduct facil
final stock trade peer sinc cynosur acquisit
recess concern emerg see defens choic volatil
inflect market recur revenu provid predict
less risk recess scenario would also see smaller impact peer
macro risk intens much smaller intern busi exposur
stock ytd vs ytd life
scienc tool index med-tech name ihi believ still
signific potenti upsid two vertic busi breast health
molecular diagnost vertic expand current offer
ramp-up consum servic spend mid-singl digit growth rate
sustain breast health driven continu upgrad cycl clear global leader
posit digit mammographi potenti regulatori tailwind expand portfolio
breast health suit diagnost side believ molecular diagnost
busi deliv high singl digit growth next year expand menu pull-
upsid well continu panther placement unit current
believ grow sale organ ex-blood screen
upsid potenti deliv high-singl digit low-doubl digit ep
growth despit concern ou strength sustain current compani
lever significantli reduc exit gen-prob acquisit
given strong cash flow metric continu util balanc sheet
smaller tuck-in acquisit augment top-lin growth share buyback
strong recur revenu stream account top-lin
recess concern emerg investor increasingli look valu stock
gener recur revenu less risk predict oppos
myth capital-heavi compani actual recur
revenu includ revenu diagnost consum surgic
consum dispos instrument novasur myosur well
servic revenu breast health segment year total
revenu base come capit sale primarili
mammographi system cynosur laser expect target spend
diagnost imag sustain optim capit budget among hospit
benefit base bofaml proprietari hospit capital-expenditure survey conduct
facil link recent survey capital-expenditure outlook
promis hospit expect capital-expenditure increas fewer expect
decreas first time sinc access capit look easier
respond look difficult
mammographi instrument upgrad on-going regulatori tailwind
breast cancer affect women us common
cancer women global million new case diagnos believ
mammographi tomosynthesi opportun
penetr within instal base anoth
year left upgrad cycl number player us mammographi
market share mammographi provid fda-
approv indic dens breast march fda propos amend
modern mammographi servic requir breast densiti report
promot adopt system benefit need
uniform breast densiti report enact
competit market lead signific
continu benefit first-to-market leadership clinic
differenti gantri fda-approv indic dens breast discuss
larger peer struggl gain traction esp us believ rest
player primarili ge siemen fujifilm collect place unit
year vs around see limit risk new market entrant
imag superior technolog clinic data believ holog
continu gain share digit mammographi market
tuck deal add current offer could acceler growth
look growth ancillari imaging/biopsi product provid
opportun bundl potenti win larg health system drive breast
health busi grow sustain mid-single-digit rate follow
launch affirm prone brevera biopsi system close addit tuck-in
deal breast health space faxitron focal acquisit
recent announc pend acquisit superson imagin
enter ultrason market grow high-single-digit rate upon close holog
typic spend annual tuck-in deal compani plenti
dri powder free cash flow continu add current offer may
provid upsid factor addit acquisit model
expand panther menu support steadi fast grow mdx busi
instal panther expand menu higher volum assay
test expect steadi fast grow mdx busi grow consist high-
singl digit low doubl digit drive overal diagnost busi sustain
mid-single-digit percentag growth us custom consolid mdx assay
combin women health virolog assay onto panther thank
continu fda clearanc assay intern panther placement still
early-to-mid inning addit work upgrad panther
platform drive adopt high-throughput lab ad scalabl flexibl
double-digit growth ou market long runway
ou market repres big opportun across busi
compani revenu intern significantli lower
compani life scienc tool diagnost med tech sector mix
manag indic ou opportun focus
invest intern capabl last three year believ
still larg opportun mammographi small portion ou
market digit fraction remain also
signific market opportun diagnost hand smaller ou
exposur temporarili benefit tariff fx impact limit
optim strain capit resourc signific consolid
hospit sector neg affect sale hospit
capit equip even without consolid hospit capital-expenditure spend tend lumpi
natur howev current outlook capital-expenditure solid expect target
spend dx imag sustain optim capit budget posit benefit
howev capit sale could impact event global recess
extrem polit risk volumes/reimburs materi worsen hospit
see medicar note hc facil team recent updat polit
ou growth may slow due macro headwind foreign exchang risk
record double-digit growth intern franchis past nine
ten quarter exclud blood-screen cynosur recent
ou growth impact latin america macroeconom factor howev multipl
intern player life scienc tool space quot european weak
recent sustain faster growth rate intern may slow due
heavi exposur eu underexpos ou compar
peer expand intern import part growth strategi
addit currenc fluctuat ou region caus revenu earn volatil
bullish current product cycl tomo panther difficult
determin major pipelin activ given manag focu take advantag
current major product offer tuck-in acquisit expand across breast
health continuum care expand assay menu panther instal base
believ compani unlik releas anyth complet new near term
longer term think medic imag field could suscept
competit genet analysi exampl number compani work
detect breast cancer blood could disrupt tradit imag howev
believ like year away especi difficult breast cancer given
extrem well establish infrastructur guidelin mammography-bas breast
cancer screen vs blood-bas test genet base test mdx
busi defend market posit point-of-care/lab
decentr movement could make inroad infecti diseas test reduc
competit larg entrench player
compet larg entrench player breast imag ge
siemen fuji global player molecular dx roch abbott
may hamper tri penetr
intern market howev believ advantag smaller
player nimbl focus demand custom
also face competit host compani across in-vitro diagnost
surgic medic aesthet landscap one competitor develop
superior product compani busi could harm
busi expos regulatori fda risk clinic
practic guidelin risk extent exampl liquid cytolog busi
affect elong pap test interv went everi year
everi year prior medic devic must undergo rigor lengthi
evalu fda prior market approv new product may approv
time could subject product recal regulatori agenc may also
decid heighten scrutini certain industri exampl cynosur busi
neg impact fda warn letter medic aesthet
industri issu juli concern fulli address novemb
guarante regulatori action would happen
focus tuck-in acquisit last two year
manag made decis acquir cynosur go medic aesthet
earli well receiv street return invest
much lower expect cynosur less controversi busi may
never fulli recov gener enough clinic data medic
offer especi one cynosur main product monalisa touch
said manag yet make major acquisit remain
seen fare go forward
intellectu properti ip risk litig product liabil
like continu target ip lawsuit given expans
product offer current litig minerva surgic novasur
abiomerieux hiv product fujifilm mammographi system
believ litig repres materi fiscal risk compani also
subject liabil claim relat error defect instrument servic
variou clinic offer may harm busi result financi
holog uniqu product profil molecular diagnost
make find perfect comp challeng thu choos comp mix
compani space exhibit holog comp larg cap
trade price-to-earnings premium diagnost comp median
ep trade discount dx peer discount
med-tech peer discount blend median comp set
believ trade closer peer group core growth improv
next year peer grow trade averag
highlight exhibit
trade under-perform larg cap
med-tech name well life scienc tool servic index sinc
cynosur acquisit exhibit recent share close gap vs
life scienc index widen out-performance vs
rais ep reflect higher organ growth
rate forecast ex-blood screen report growth rais
sale margin est margin driven oper effici initi sale
mix po base ep repres discount vs
exhibit holog trade diagnost med-tech comp compani grow compound-annual-growth-rate trade averag ep
mn valu mn
exhibit outperform trade larg cap med-tech name past five year
yellow solid line composit total return med-tech peer includ
bofaml estim consensu
line street sales/ep
street estim sale
ahead street ep
exhibit present summari revenu ep forecast rel
exhibit bofaml vs consensu sale adjust ep estim
mn ex ep
sensit analysi base project tabl base
case assum organ revenu growth
improv gross margin gm annual oper margin opm
expans slight share count reduct compani plan stay activ
buyback
bull model organ revenu growth
continu intern expans addit product offer
tuck-in acquisit allow faster revenu growth servic
consum compon flow margin drive increment
gross margin expans opm benefit result
earn given sustain growth profil
oper improv stock may move closer peer
trade correspond impli valuat
bear model organ revenu growth deceler rapidli
recess scenario competit begin
take share would flow hurt gross margin vs
base increment oper expens maintain compani
lead market posit result opm vs base case
lead earn coupl compress
multipl trade past three year result
tabl scenario analysi calendar year estim
leader women health
headquart marlborough massachusett oper countri
leader women health industri number one
market share us mammographi market liquid-bas
cytolog market cervic cancer screen ct/ng chlamydia
trachomatis/neisseria gonorrhoea std test market gynecolog
surgeri equip market compani also expand share molecular
diagnost market recov impact hasti invest
medic aesthet busi acquisit cynosur
found narrowli focus bone densitometri digit x-ray
compani much chang past three decad acquisit
transform lead women healthcar compani broad product portfolio
med tech diagnost sinc acquir mammographi
biopsi asset constitut breast health continu ad
breadth offer expand diagnost
purchas cytc thinprep liquid cytolog thirdwav cervista hpv
gen-prob aptima assay tigri panther instrument blood screen
busi today diagnost second largest busi
sale see chart chart
breast health diagnost account sale
oper five differ busi segment chart breast health
revenu diagnost gyn surgic medic aesthet
skelet health sep end report revenu
y/i organ constant currenc recent june end
compani report top-lin report growth y/i organ
growth ex-blood screen constant currenc
recur revenu mix make holog defens choic
oppos histor imag capit equip vendor actual
gener recur revenu includ approxim revenu
diagnost consum assay surgic consum dispos
instrument novasur myosur well servic revenu
breast segment year also make
effort improv assay util mdx boost breast health servic compon
may drive recur revenu upsid
revenu base come capit equip sale primarili
mammographi system dx instrument cynosur laser see chart
discuss capital-expenditure spend trend later section amid concern recess see
defens choic growth valu rotat volatil
inflect market overal revenu recur potenti increas
share provid predict less risk recess scenario
domest exposur peer limit tariff fx risk
geograph maintain fairli consist mix profil despit variou
acquisit last year deriv sale us due
strong posit mammographi diagnost chart one highest
domest exposur across coverag univers suggest limit trade tariff
fx impact intern europ primarili target franc germani uk make
total sale mix follow asia-pacif apac mainli china australia
japan rest world row account includ canada
latin america middl east intern growth bit slower
recent quarter due chiefli macroeconom polit headwind
holog small latin america busi mostli breast health compani
expect improv busi still y/i
chart sale mix revenu recur less
chart sale mix geographi one highest domest
exposur among tool diagnost med tech peer
expand breast health busi
breast health made sale well recent
quarter breast cancer affect women us
common cancer women global million new case diagnos
approxim women us age
age rang recommend mammographi screen averag risk popul
major polici group see tabl approxim adher annual
biannual screen recommend drive consist mammographi
instrument demand despit competitor nois remain number
manufactur mammographi instrument us
estim market share clear global leader digit mammographi
owe domin technolog think driver breast health
five differ categori discuss
tuck-in acquisit expand across breast health continuum care
expand across breast health suit acquisit
recent year expand suit breast health product
tuck-in acquisit improv origin geniu system includ
perform gantri imag sale made major
breast health busi chart offer full
suit breast health product includ radiolog patholog surgeri exhibit
mammographi system read station
 minim invas breast biopsi guidanc system devic
 breast conserv surgeri product faxitron focal acquisit
chart breast imag account major holog breast health busi
ad ancillari imaging/biopsi product provid opportun
bundl potenti win contract larg health system follow
launch affirm prone biopsi tabl brevera biopsi system real-tim specimen
x-ray system compliment affirm tabl think affirm prone
opportun includ instrument servic sale
next year
close addit tuck-in deal breast health space
faxitron focal acquisit faxitron bring portfolio product local
rfid wireless breast lesion local system launch visionct
breast specimen-design ct system local use identifi breast lesion
implant local tag insid patient breast use portabl
handheld reader exhibit pinpoint exact locat breast lesion breast
tissu remov surgeri tradit wire involv pinpoint locat
surgeri focal ad biozorb offer complet breast
health portfolio screen biopsi final surgeri
exhibit local pinpoint exact locat breast lesion breast tissu remov surgeri without wire
june announc pend acquisit french-bas ultrason
provid superson imagin ssi complet acquisit would
allow address global cart-bas breast ultrasound market
opportun grow high-single-digit rate core breast health
growth launch mach ssi reach revenu
expect reach growth accord
consensu ssi product also complement wireless handheld ultrasound
scanner viera market partnership clariu mobil
difficult pars exact spend diagnost imag within hospit
capit expenditur capital-expenditure accord bofaml proprietari us hospit capital-expenditure
survey conduct facil link latest report gener
diagnost imag equip capital-expenditure spend prioriti hospit
sinc begin chart continu top prioriti
respond sinc
chart capit spend prioriti time gener diagnost imag top capital-expenditure spend prioriti hospit us
data reflect capital-expenditure equip type hospit identifi equip capital-expenditure prioriti term capit spend current year exclud healthcar
bofaml proprietari capital-expenditure survey also monitor mammographi capit
spend prioriti sinc recent survey us
hospit survey across state indic mammographi top capit
spend categori chart past quarter mammographi also
consist rank top capit spend categori statist
categori like gener diagnost imag hospit bed robot surgeri remain
encourag data given mammographi much narrowli defin
expect target spend dx imag sustain optim capit
budget chart benefit recent survey capital-expenditure outlook
improv particip prior survey indic
expect hospit spend hospit expect capital-expenditure
reduct solidli prior survey
chart capit spend prioriti gener diagnost imag latest survey exclud healthcar
chart major hospit expect capital-expenditure rise respond prior indic expect hospit spend
denot yellow solid line hospit expect capital-expenditure reduct blue dot line solidli prior survey
enter us mammographi market receiv approv
selenia full field digit mammographi ffdm instrument prior breast
x-ray store directli film analog made record difficult maintain
share analyz earli ge becam first vendor receiv fda approv
ffdm instrument follow fischer imag siemen despit
entranc multipl vendor reimburs decis digit film
screen technolog advanc convers digit peak
start sell digit tomosynthesi gantri earli adopt
allow radiologist view imag breast allow better tissu
visual higher detect rate well lower recal rate fals posit vs
ffdm gantri may becam first vendor receiv fda
approv effect unchalleng market share ge receiv
approv gantri august follow siemen april
fujifilm januari howev replac peak unit happen
assum year replacement/upgrad cycl come
anoth upgrad cycl launch premium product
higher end system improv imag qualiti new detector new patient
comfort featur virtual system today upgrad
holog penetr us year left upgrad cycl
penetr instal base
unit us overal market place gantri
steadi cadenc sinc quarter assum
current convers rate would place current
accord fda monthli mqsa nation statist
accredit unit us septemb therefor unit
perspect share us rate
anoth year left upgrad cycl clinic differenti gantri
also win share us abroad
beyond gantri placement continu smaller piec breast health busi
compani move toward recurring-bas servic model leverag
expand instal base chart servic revenu compon larger
instrument revenu compon us primarili relat multi-year servic
contract upon unit placement grow low singl digit rate along
growth instal base
regulatori polici tailwind may boost upgrad
march fda propos amend improv mammographi qualiti
requir breast densiti report first amend year propos
prompt increas use system need uniform breast densiti
report enact propos would amend regul mammographi
qualiti standard act mqsa went effect mammogram
dens breast obscur sign breast cancer lower sensit imag
dens breast also identifi risk factor develop breast cancer recal
mammographi provid fda-approv indic dens
breast legisl drive toward disclos breast densiti clearli play
compani advantag grant legisl effort may take time enact breast
health busi benefit polici tailwind
also benefit public larg studi show benefit
vs mammographi base total mammographi exam friedewald sm
rafferti ea sl et al better medicar reimburs rule vs
sinc accord recent yale studi base analysi
patient mammographi data richman et al track replac
standard care breast cancer screen adopt grew
approxim similar trend across medicar patient
commerci insur interestingli studi fund part american
cancer societi ac one impact polici group endors
specif routin screen method updat breast
cancer screen guidelin due lack data comparison
us prevent servic task forc uspstf also indic insuffici evid
assess benefit gantri last guidelin updat
american colleg radiolog support use quot better detect rate
lower fals posit rate practic guid tabl ac state
revisit recommend updat guidelin evid becom
avail led us believ might upcom guidelin tailwind
tabl breast cancer screen guidelin major polici group may updat data avail
obstetrician
gynecologist
agenc
research
insuffici evid
recommend
screen
screen
mammographi clinic
american colleg
physician
screen
discuss benefit
harm women
good health order
screen
two year woman
request
famili
decis start
mammographi
individu one
women place
higher valu
potenti benefit
potenti harm may
choos begin
screen
physician
year average-risk
biennial screen
mri tomosynthesi
breast self-exam
recommend
evid insuffici
assess benefit
harm clinic
breast exam dbt
acr indic
practic paramet
dbt help mitig
mask effect
result decreas
fals posit
examin
concomit increas
detect malign
compar
women age
mammographi
women age
suggest
screen
risk death
breast cancer
current
decis start
mammographi
women prior age
year
place higher
valu potenti
benefit
choos begin
age
year
women age
year
choic start annual
screen
mammogram
wish
risk screen
well potenti
benefit
age year
get
women age
year get
year older
switch
year
choic continu
mammographi
screen
mammographi clinic
current evid
insuffici assess
benefit harm
digit breast
primari screen
method breast
women
familiar
limit
associ breast
also
familiar
feel report
chang
cdc center diseas control prevent bofa merril lynch global research
us largest market near term due tomo upgrad cycl see
signific opportun breast health busi ou intern digit
mammographi adopt adher markedli trail us
focus invest intern capabl last three year
believ still larg opportun mammographi one-
third ou market digit fraction remain
breast cancer incid rate quickli rise china increas focu
prevent via earli detect assum share
mammographi market outsid us major intern market particip includ
ge siemen philip exhibit
ou placement still earli inning
unlik us mammographi system instal base
convert digit instrument outsid us instal base like
mammographi unit still approxim analog therefor
focus convert global analog instal base digit platform first
push thu place much higher percentag unit vs
ou compar us compani focus geographies/countri
western europ uk canada australia japan brazil china
estim instal base unit global
assum us unit instal repres
global mix suggest tomo unit outsid us
expect overal breast health grow mid-singl digit constant
currenc overal ou busi grow high-singl digit constant currenc
ou breast high-singl low doubl digit rang
magnet reson ultrasound digit mammographi strong across vertic
individu market struggl macroeconom uncertainti
market latam neg impact recent gener
volum look healthi global see defens choic volatil
limit risk new market entrant
imag market limit risk new market entrant summar
major compani space product posit exhibit top
supplier siemen ge philip toshiba broadest offer strongest
posit vendor tend focu specif modal compet top
effect exampl number mammographi compani
us hitachi best known ultrasound equip despit quit broad
portfolio fuji strong gener x-ray product
chines market still prefer domest name includ mindray
unit imag prefer home grown chines compani
grown past unit imag tri break us imag market
made debut rsna radiolog societi north america annual
confer launch fda-clear system mri pet/ct us
market posit us still earli stage digit mammographi
yet core part offer
holog lead market signific
continu benefit first-to-market leadership larger
peer struggl gain traction esp us estim rest player
primarili ge siemen fujifilm collect place unit year vs
around number-two player us ge receiv fda
approv senograph pristina system siemen number-thre receiv
fda clearanc new mammomat revel hd breast biopsi solut
still earli stage placement fujifilm launch first
instrument cristal us jan afford price point
limit market capac us may seek allianc
promot product
exhibit siemen ge philip toshiba broadest offer strongest posit vendor tend focu specif modal
bofa merril lynch global research compani report
via acquisit brevera biopsi system real-tim specimen x-ray system compliment breast biopsi
pend acquisit superson imagin ssi french-bas ultrason provid
philip announc global partnership collabor offer mammographi technolog philip portfolio ultrasound mri ct x-ray system
holog diagnost busi account approxim total revenu
well recent quarter sale platform current
molecular diagnost mdx grow high singl digit low doubl
digit organ cytolog perinat rel flat low single-digit growth
global yoy rest divest blood screen busi continu
gener residu contract servic revenu declin see chart
instal expand menu higher volum assay test expect
steadi fast grow mdx busi drive overal diagnost busi
chart mdx account half dx busi
holog molecular diagnost busi compris instrument panther
tigri assay women health virolog fda approv
assay continu grow test menu women health assay
primarili well virolog assay discuss holog mdx busi well
broader mdx market
panther instal global system
outsid us compani continu increas panther util
expand menu total mdx grew led molecular diagnost mdx
perform growth us ou us custom
consolid mdx assay combin women health plu virolog
assay onto panther thank continu fda clearanc assay intern
panther placement still earli inning
holog autom mdx test platform panther first releas eu
origin manufactur gen-prob clear fda
year gen-prob acquir system initi target low
medium throughput lab older system tigri target high-throughput
launch hardwar updat panther fusion add pcr polymeras
chain reaction compon panther exhibit avail full system add-
exist panther system fusion modul menu expans help
compet mdx system develop fusion open access platform
also allow lab consolid ldt lab-develop test workflow onto
panther open door work esoter lab
exhibit panther fusion hardwar addit attach panther system add pcr capac allow open access
right panther fusion side-car attach stand-alon panther
term pull-through report throughput grow high-
singl digit rate expand menu tabl pull revenu expect
increas panther system typic use approxim capac
approxim custom run assay panther oppos
fda-approv assay avail believ virolog also repres upsid
time given signific panther footprint although revenu base
small think women health assay remain strateg focu
tabl holog assay menu focus sti women health virolog
herp
adenoviru human metapneumoviru rhinoviru
america merril lynch global research compani data
aptima combo assay ct/ng
addit add-on better serv lab size
may also announc three upgrad panther platform drive
adopt high-throughput lab ad scalabl capac walkaway time
throughput flexibl enabl virtual physic linkag panther system
three add-on modul exhibit includ panther panther link panther
trax expect launch next year scale-up panther intend
drive placement larger lab labcorp lh
smaller clinic lab gradual close/consolid larger refer lab see
clinic laboratori primer import capabl address higher
exhibit ad scalabl solut panther system better serv high throughput lab
mdx market continu grow doubl digit well overal ivd market
broader mdx market project grow global fastest grower
across ivd in-vitro diagnost space accord iqvia estim aacc
annual analyst brief virolog largest vertic within mdx chart
share includ assay viral load like hiv quant hcv quant hbv quant well
qualit test genotyp test virus like hpv human papillomaviru infect
hsv herp simplex viru genom becam second largest test segment
mdx make market includ test genet mutat
growth genom vertic significantli outpac vertic
past year bacteriolog market includ test like chlamydia
gonorrhea ct/ng mrsa methicillin resist staphylococcu aureu final blood
screen total mdx market made standard qualit assay
blood donation/transfusion/organ transplant etc
chart share global mdx market
chart mdx market test type
market diagnost intern bofa merril lynch global research estim
market diagnost intern bofa merril lynch global research estim
market virolog bacteriolog blood screen combin repres
mdx market grow low-to-mid singl digit rang
genom grow materi higher double-digit rate price rel
stabl dx space pama protect access medicar act head third-
year topic constantli come contract negoti price
pressur noth new clinic lab space
compet larg diversifi market differenti focus product
roch long-stand leader mdx space share global
market per market diagnost intern updat
associ molecular patholog annual confer roch particip across
vertic particular strength europ ou region beyond roch
mdx market rel fragment via cepheid novarti
grifol abbott biomerieux share chart
believ share broader mdx market
sizabl upsid diagnost especi ou exampl molecular diagnost
market eu current occupi
also scale hiv viral load monitor program africa
market approxim howev core lab test market holog
compet larg diversifi market broad clinic area top ivd
name broader test menu develop special
roch particip across vertic particularli strong oncolog
biomark special gastric lung breast cancer
abbott broad diagnost portfolio address core lab mdx point care well
transfus medicin abbott tradit strength lie infecti diseas
hepat own signific share total immunoassay market abbott
high-throughput platform approv back test menu
includ cmv hiv hbv hcv ct/ng zika
acquisit cepheid particip almost everi
major bucket diagnost market small footprint mdx
landscap cepheid provid lead molecular diagnost platform
genexpert offer fulli integr solut test area infecti
diseas oncolog women health
siemen one broadest test menu market assay
market leader core lab offer point care solut
small foot print mdx
panther integr mdx menu domin std women health test
market viral load test assay grow rapidli addit panther
fusion add-on ad pcr capabl respiratori assay also allow lab
consolid ldt lab-develop test workflow onto open access
panther ou revenu grow double-digit consist past year
compani invest ou infrastructur past two year
build commerci capabl therefor expect see sustain growth
ou coupl mix capabl
overal dx busi believ mid-single-digit percentag growth
sustain chiefli drive mdx panther growth potenti market
share upsid may rang bound central lab test market often favor breadth
rather specialti
accord third parti estim liquid-bas pap test cervic cancer
screen market global believ share
market lead liquid-bas cytolog thinprep introduc thinprep
wide adopt pap test us market share
share ou thinprep main competit liquid pap surepath
intern thinprep also compet variou non-fda approv test
us cytolog market growth remain challeng due exist high
market share longer cervic cancer test interv five-year interv previous
women encourag get tradit pap test annual liquid-bas test
like thinprep biennial interv lengthen everi year
women age women age encourag get either combin
screen pap hpv test everi year
given guidelin chang bd seen substanti declin
cytolog busi last sever year though headwind mostli settl
declin rate plateau us busi current flattish slightli
roughli off-set intern growth overal thinprep remain core
strength given key role women health abil run sever
mdx assay collect vial busi also seen improv
focu sale team cross-sel thinprep aptima hpv co-test
continu innov cytolog recent receiv fda clearanc ce-
mark thinprep genesi imag facilit co-test thinprep
aptima hpv assay expect legaci busi continu current trend
rest screen interval-rel headwind abat
holog fetal fibronectin ffn test single-us dispos test analyz
compani tli iq access likelihood pre-term birth birth week
test look presenc fetal fibronectin protein biomark
correl pre-term deliveri happen us pregnanc
women week take test determin likelihood deliv
within next two week test repeat often everi two week
week
recent ffn fda-approv test predict risk pre-term birth
april fda approv partosur test assess risk
spontan pre-term birth symptom pre-term labor sever studi show
improv posit predict valu partosur ffn howev sensit
partosur around women deliv within day melchor et al
et al sensit around ffn accord accord
studi kiefer partosur may lower fals posit rate ffn
may better sensit data
holog ffn also face competit reproduct health techniqu
use ultrasound assess likelihood pre-term expect perinat busi
rel flat
blood screen divest servic tailwind continu
decemb announc divestitur blood screen busi
long-tim partner grifol novarti annual sale
divestitur close januari blood screen busi one
profit busi segment within grow low-
single-digit rang deal dilut compani oper margin time
allow sale growth acceler smoother growth trajectori dx
busi recal blood screen tender-bas thu lumpi
sinc divestur blood screen continu gener residu revenu
relat low margin product servic us transit agreement
grifol expect blood screen revenu
declin
surgic biz tale two citi
gyn surgic account sale primarili focus
treat gynecolog condit like abnorm uterin bleed gyn surgic
form two acquisit acquisit cytyc novasur technolog
acquisit myosur technolog novasur global
leader endometri ablat market stagnant increas competit
also slight reduct averag sell price across mani myosur
novasur devic partial off-set increas sale volum
higher price novasur new devic surgic busi saw declin
improv sinc believ segment continu
current trajectori low singl digit percentag growth
myosur growth engin new product drive volum
myosur minim invas hysteroscop tissu remov system fibroid polyp
patholog within uteru caus abnorm uterin bleed
affect everi women hysteroscop tissu remov excav
tissu remain intact allow test abnorm myosur sold four
variat reach xl manual remov tissu vari size wide
rang locat new product offer also drive volum growth fluent
fluid manag system launch offer advanc technolog
streamlin oper room workflow simplifi setup
potenti annual opportun us affect
women annual asp holog hysteroscop tissu remov market share
 myosur compet hysteroscop loop resect smith
nephew truclear tissu morcel symphion hysteroscopi
novasur declin lessen multi-year process
heavi menstrual bleed menorrhagia hmb frequent problem
lead anemia affect one five menstruat women common
women age first line treatment includ use nonsteroid anti-
inflammatori drug nsaid oral contracept
follow first-lin option levonorgestrel-releas intrauterin lng-iud
mirena bayer popular solut women want preserv
fertil mirena implant non-invas either gener practition
gynecologist devic releas steadi amount progestin help
control bleed howev solut work patient
replac everi five year iud approv fda use unit state
treat heavi period
women complet childbear endometri ablat ea option
novasur market lead solut share endometri
ablat market player includ boston scientif genesi system
coopersurg novasur one-tim five-minut non-invas procedur
perform gynecologist novasur perman remov endometrium line
uteru caus bleed deliv radio frequenc energi devic
approv fda septemb use wide sinc approv
intermediari less-perman iud solut invas
hysterectomi procedur remov uteru
novasur sale declin lessen slowli sure
seen increas competit stagnant market endometri ablat
novasur market novasur sale declin past sever
year addit devic competit drug therapi hormon drug intrauterin
devic hysterectomi etc altern novasur procedur manag
focus stabil novasur declin lessen
return flat growth still seem like multi-year process
cynosur bet pay
februari announc acquisit cynosur cyno
cash ev subsequ close march cyno compet
medic aesthet market offer bodi contour
sculpsur laser tattoo hair remov elit icon women health
monalisa touch/mlt vitalia cyno intend add higher-growth self-
pay revenu stream women health franchis margin cash flow low
rel opm vs ex blood start
deal kept fail deliv high growth expect manag sinc
written
histori medic aesthet compet larger
experienc name compani also deal regulatori headwind
time time juli receiv fda letter along number
compani oper industri voic concern industri
subsequ voluntarili recal tempsur vitalia handpiec unus probe
tempsur system market vitalia specif mention fda
letter vitalia later put back market novemb compani
receiv confirm fda adequ address
concern express agenc letter
meaning turnaround expect near-term
time strength ob-gyn market edg women health
screening/surgeri could expand cynosur product user base differenti
competitor zeltiq expect transit happen
time soon regard regulatori concern compani pursu clinic trial
gener data discuss fda regard mlt trial data
year market side celebr spokesperson brook shield
anecdot drive momentum sculpsur cynosur manag team also
work in-licens aesthet product element drive growth
expect effort take time
sale forc stabil come easi comp
compani lap fda warn letter management indic busi roughli
break-even subject quarterli lumpi opinion cynosur core part
busi current less overal revenu mix compani
took pain cynosur controversi cynosur
longer key part convers among invest commun
skelet health oldest smallest
skelet oldest busi segment also smallest
sale indic acquisit histori skelet platform
two main product x-ray bone densitomet real-tim x-ray imag
c-arm bone densitometri tool enabl diagnosi monitor osteoporosi
use obes manag introduc first commerci
densitomet launch horizon line bone densitometri
addit bone densitomet sell platform mini c-arm imag
system enabl lower-cost lower intens real-tim x-ray imag typic
use orthoped surgeon perform minim invas surgeri extrem like
hand write knee foot ankl ge primari competitor bone
densitometri market compet orthoscan mini-c arm market
recent compani saw increas volum horizon dxa system partial off-set
lower sale volum insight fd mini c-arm system expect segment retain
current low-to-mid singl digit growth forese futur
organ revenu growth upsid potenti
compani guid organ growth end guid
come quarter model organ growth includ blood
screen ex-blood screen believ potenti
upsid organ growth case
margin profil see improv
experienc gross margin headwind year fx tariff
impact account half rest due unfavor mix higher
servic cost move forward expect tariff relief given time new product
contribut help improv margin profil model margin
improv y/i
capit deploy plan tuck-in buyback
first three quarter deploy
share repurchas compani view neg hasti move medic
aesthet cynosur acquisit stock lag
peer past quarter manag indic tuck-in deal
complement exist offer total budget annual would
strateg focu instead high-premium transit acquisit new
budget bolt-on deal compani plenti dri powder
free cash flow continu add offer either breast health suit
diagnost franchis pay debt current well remain activ
share buyback model purpos factor unannounc
acquisit number
remain buy-back author sinc
compani spent year averag share
repurchas expect compani continu buy-back activ boost
total revenu
incom tax effect reconcil item
adjust detail
 sale
sg sale
depreci sale
amort sale
cash equival
properti plant equip net
current portion long-term debt
long-term debt net current portion
total liabil stockhold equiti
adjust reconcil net loss incom net cash provid oper activ
loss dispos properti equip
chang oper asset liabil
prepaid expens asset
accru expens liabil
net cash provid oper activ
acquisit busi
proce sale busi net cash transfer
purchas properti equip
increas equip custom usag agreement
proce sale matur invest secur
increas decreas asset
net cash use provid invest activ
repay long-term debt note payabl
proce issuanc convert note net issuanc cost
payment debt issuanc cost
payment conting consider
net cash use financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
po base approxim calendar ep estim
ahead three-year histor averag compani diagnost
med-tech peer multipl believ higher histor multipl
justifi given organ growth upsid breast molecular diagnost
downsid risk po competit pressur slower uptak reimburs
new product unfavor chang clinic practic guidelin manag
departur regulatori risk faster declin legaci busi
upsid risk po faster growth core diagnost mammographi
gynecolog surgeri end market improv cynosur
synergi addit tuck-in deal
ivi herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
